Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study to Determine the Safety and Recommended Phase 2 Dosing of Zeaxanthin Alone or in Combination With Pembrolizumab in Patients With Metastatic Solid Tumors

NCT05232409 is registered in ClinicalTrials.gov with Valley Health System as lead sponsor.

NCT NCT05232409
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05232409 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study to Determine the Safety and Recommended Phase 2 Dosing of Zeaxanthin Alone or in Combination With Pembrolizumab in Patients With Metastatic Solid Tumors
Lead sponsor
Valley Health System
Phase
Phase 1
Overall status
Recruiting
Start date
April 17, 2022
Completion date
March 31, 2028
Enrollment
72 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cancer metastatic, metastatic solid tumor